SELLAS Life Sciences Group, Inc. (SLS) vs Viridian Therapeutics, Inc. (VRDN)
A side-by-side comparison of SELLAS Life Sciences Group, Inc. and Viridian Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
SLS
SELLAS Life Sciences Group, Inc.
$11.43HealthcareDelayed quote: Oct 6, 2026, 3:15 PM EDT
VRDN
Viridian Therapeutics, Inc.
$18.16HealthcareDelayed quote: Oct 6, 2026, 3:15 PM EDT
Total return — SLS vs VRDN
growth of $100 · dividends reinvested · last 10ySLS -99.9% (-49.4%/yr)VRDN -83.3% (-16.4%/yr)VRDN compounded faster over this window
Log scale — wide-divergence pair
SLS VRDN
SLS vs VRDN: by the numbers
- •SLS is the larger company ($2.13B vs $2.06B market cap).
- •Both run net losses; SLS's is the smaller (0.00% vs -544.06% net margin).
Metrics side by side
Valuation
| Metric | SLS | VRDN |
|---|---|---|
| P/S ratio | N/A | 28.92 |
| P/B ratio | 15.44 | 3.65 |
Profitability
| Metric | SLS | VRDN |
|---|---|---|
| Gross margin | 0.00% | 99.55% |
| Operating margin | 0.00% | -512.91% |
| Net margin | 0.00% | -544.06% |
| ROE | -23.58% | -58.45% |
| ROIC | -25.45% | -39.18% |
Growth (annualized)
| Metric | SLS | VRDN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 93.92% |
| Total return CAGR (5Y) | 6.20% | 1.64% |
Frequently asked
- How have SLS and VRDN total returns compared?
- Over the past 10 years, SLS delivered -49.07% and VRDN delivered -16.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
SELLAS Life Sciences ROEViridian Therapeutics ROESELLAS Life Sciences operating marginViridian Therapeutics operating marginSELLAS Life Sciences revenue growthViridian Therapeutics revenue growthSELLAS Life Sciences free cash flowViridian Therapeutics free cash flow
SELLAS Life Sciences & Viridian Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.